Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma.
Phase Ib Clinical Study Evaluating the Efficacy and Safety of TQB2223 Injection Combined With Penpulimab Injection in the Treatment of Advanced Hepatocellular Carcinoma
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Terminated
This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.
Other terminated trials from Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Extensive Stage Small Cell Lung Cancer · Apr 2026
- Myelofibrosis · Phase PHASE1/PHASE2 · Dec 2025
- Advanced Endometrial Cancer · Phase PHASE2 · Nov 2025
- Breast Cancer · Phase PHASE1/PHASE2 · Nov 2025
- Dedifferentiated Liposarcoma · Phase PHASE2 · Sep 2025
More terminations from Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Other Advanced Hepatocellular Carcinoma trials with similar outcome
A PHASE1 clinical study on Advanced Hepatocellular Carcinoma, this trial is terminated or withdrawn. The trial is conducted by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and has accumulated 5 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Dec 2025 — Present [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Dec 2024 — Dec 2025 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Dec 2024 [monthly]
Not Yet Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .